Lupin and Zydus Partner to Co-Market Semaglutide Injection in India
Loading more articles...
Lupin, Zydus Partner to Co-Market Semaglutide Injection in India
C
CNBC TV18•17-03-2026, 13:31
Lupin, Zydus Partner to Co-Market Semaglutide Injection in India
•Lupin Ltd and Zydus Lifesciences Ltd announced a licensing and supply agreement to co-market an innovative semaglutide injection in India.
•The partnership aims to expand access to advanced therapies for diabetes and weight management using a patient-friendly reusable pen device.
•Lupin will co-market the drug under brands Semanext and Livarise, while Zydus will continue with Semaglyn, Mashema, and Alterme.
•Lupin will pay Zydus upfront licensing fees and milestone-based payments.
•The collaboration combines Zydus’ product development with Lupin’s distribution network to strengthen their presence in India's growing market for diabetes and obesity treatments.
